National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 76168-76169 [2011-31296]
Download as PDF
76168
Federal Register / Vol. 76, No. 234 / Tuesday, December 6, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0824]
Regulatory Site Visit Training Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA’s) Center for
Biologics Evaluation and Research
(CBER) is announcing an invitation for
participation in its Regulatory Site Visit
Training Program (RSVP). This training
program is intended to give CBER
regulatory review, compliance, and
other relevant staff an opportunity to
visit biologics facilities. These visits are
intended to allow CBER staff to directly
observe routine manufacturing practices
and to give CBER staff a better
understanding of the biologics industry,
including its challenges and operations.
The purpose of this document is to
invite biologics facilities to contact
CBER for more information if they are
interested in participating in this
program.
DATES: Submit either an electronic or
written request for participation in this
program by January 5, 2012. The request
should include a description of your
facility relative to products regulated by
CBER. Please specify the physical
address(es) of the site(s) you are
offering.
ADDRESSES: If your biologics facility is
interested in offering a site visit, submit
either an electronic request to https://
www.regulations.gov or a written
request to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. If you
previously responded to earlier requests
to participate in this program and you
continue to be interested in
participating, please renew your request
through a submission to the Division of
Dockets Management.
FOR FURTHER INFORMATION CONTACT:
Lonnie W. Henderson, Division of
Manufacturers Assistance and Training,
Center for Biologics Evaluation and
Research (HFM–49), Food and Drug
Administration, 1401 Rockville Pike,
Suite 200N, Rockville, MD 20852–1448,
(301) 827–2000, FAX: (301) 827–3079,
email: industry.biologics@fda.gov.
SUPPLEMENTARY INFORMATION:
jlentini on DSK4TPTVN1PROD with NOTICES
SUMMARY:
I. Background
CBER regulates certain biological
products including blood and blood
VerDate Mar<15>2010
17:04 Dec 05, 2011
Jkt 226001
products, vaccines, and cellular, tissue,
and gene therapies. CBER is committed
to advancing the public health through
innovative activities that help ensure
the safety, effectiveness, and availability
of biological products to patients. To
support this primary goal, CBER has
initiated various training and
development programs, including
programs to further enhance
performance of its compliance staff,
regulatory review staff, and other
relevant staff. CBER seeks to
continuously enhance and update
review efficiency and quality, and the
quality of its regulatory efforts and
interactions, by providing CBER staff
with a better understanding of the
biologics industry and its operations.
Further, CBER seeks to enhance: (1) Its
understanding of current industry
practices and regulatory impacts and
needs and (2) communication between
CBER staff and industry. CBER initiated
its RSVP in 2005. Through these annual
notices, CBER is requesting that those
firms that have previously applied and
are still interested in participating
reaffirm their interest. CBER is also
requesting that new interested parties
apply.
II. RSVP
A. Regulatory Site Visits
In this program, over a period of time
to be agreed upon with the facility,
small groups of CBER staff may observe
operations of biologics establishments,
including for example, blood and tissue
establishments. The visits may include
the following: (1) Packaging facilities,
(2) quality control and pathology/
toxicology laboratories, and (3)
regulatory affairs operations. These
visits, or any part of the program, are
not intended as a mechanism to inspect,
assess, judge, or perform a regulatory
function, but are meant to improve
mutual understanding and to provide an
avenue for open dialogue between the
biologics industry and CBER.
B. Site Selection
CBER will be responsible for all travel
expenses associated with the site visits.
Therefore, selection of potential
facilities will be based on the
coordination of CBER’s priorities for
staff training as well as the limited
available resources for this program. In
addition to logistical and other resource
factors to consider, a key element of site
selection is a successful compliance
record with FDA or another Agency
with which we have a memorandum of
understanding. If a site visit also
involves a visit to a separate physical
location of another firm under contract
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
to the applicant, the other firm also
needs to agree to participate in the
program, as well as have a satisfactory
compliance history.
III. Requests for Participation
Identify requests for participation
with the docket number found in the
brackets in the heading of this
document. Received requests are
available for public examination in the
Division of Dockets Management (see
ADDRESSES) between 9 a.m. and 4 p.m.,
Monday through Friday.
Dated: November 30, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–31152 Filed 12–5–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.),notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications,the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Fellowships in
Digestive Diseases and Nutrition.
Date: February 21, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Thomas A. Tatham, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Translational
Research.
Date: January 26, 2012.
Time: 8 a.m. to 5 p.m.
E:\FR\FM\06DEN1.SGM
06DEN1
Federal Register / Vol. 76, No. 234 / Tuesday, December 6, 2011 / Notices
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development Notice of Closed Meeting
jlentini on DSK4TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Mentored Training
in Executive Functioning (EF).
Date: December 13, 2011.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Carla Walls, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Executive Boulevard, Rockville, MD 20892–
9304, (301) 435–6898, wallsc@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Jkt 226001
[FR Doc. 2011–31301 Filed 12–5–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Nursing Research;
Notice of Meeting
BILLING CODE 4140–01–P
17:04 Dec 05, 2011
Dated: November 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2011–31296 Filed 12–5–11; 8:45 am]
VerDate Mar<15>2010
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment program, National
Institutes of Health, HHS)
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council for Nursing
Research.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Nursing Research.
Date: January 17–18, 2012.
Open: January 17, 2012, 1 p.m. to 4:45 p.m.
Agenda: Discussion of Program Policies
and Issues.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor, C
Wing, Room 6, Bethesda, MD 20892.
Closed: January 18, 2012, 9 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, 6th Floor, C
Wing, Room 6, Bethesda, MD 20892.
Contact Person: Yvonne E Bryan, Ph.D.,
Special Assistant to the Director, National
Institute of Nursing, National Institutes of
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
76169
Health, 31 Center Drive, Room 5B–05,
Bethesda, MD 20892, (301) 594–1580,
bryany@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://www.
nih.gov/ninr/a_advisory.html, where an
agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: November 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–31302 Filed 12–5–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; ZHD1 DSR–K 58.
Date: December 14, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To provide concept review of
proposed concept review.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Administrator,
Division of Scientific Review, National
Institute of Child Health and Human
Development, 6100 Executive Boulevard,
E:\FR\FM\06DEN1.SGM
06DEN1
Agencies
[Federal Register Volume 76, Number 234 (Tuesday, December 6, 2011)]
[Notices]
[Pages 76168-76169]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31296]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.),notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications,the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Fellowships in Digestive
Diseases and Nutrition.
Date: February 21, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW., Washington, DC 20015.
Contact Person: Thomas A. Tatham, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 760, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-3993, tathamt@mail.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, Translational Research.
Date: January 26, 2012.
Time: 8 a.m. to 5 p.m.
[[Page 76169]]
Agenda: To review and evaluate grant applications.
Place: Bethesda Marriott Suites, 6711 Democracy Boulevard,
Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD, Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301)
594-8898, barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: November 30, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-31296 Filed 12-5-11; 8:45 am]
BILLING CODE 4140-01-P